Christopher Scott

Chris is Chair of Pharmaceutical Biosciences at Queen’s University Belfast (QUB) UK. Chris undertook his PhD in cysteine protease biology and activity-based probe design with Brian Walker at QUB, before continuing as a post-doc, developing the first reported activity-based probes for the bacterial transpeptidase, sortase A.  In 2001 he became a founding member of staff of a new QUB spinout company, Fusion Antibodies Ltd., a CRO that is now a leader in the development of engineered antibodies for clinical development.  In 2003, he took up his first academic position, developing his group that is focused on the development of novel antibody and nanomedicine-based therapeutic strategies.  A specific focus of his group is the lysosomal protease cathepsin S, and have developed novel protein and antibody inhibitors to target it in the tumour microenvironment, where it is deregulated.  His team are now currently evaluating novel small molecule inhibitors of cathepsin S and using these to probe its role in tumour development.


Our Sponsors